Please register and log-in to create and edit pages

User Tools

    Please register and log-in to create and edit pages

Site Tools


Main Menu

Main menu
Click categories to expand


A-Z listingplugin-autotooltip__plain plugin-autotooltip_bigA-Z listing

This is an alphabetical index of all content pages.


Other categories

Utilities

Contacts
Register

Also see

Importance Ratings
News
Legal
Donate/Sponsor


Wikenigma supports:


Feeds etc
rss / xml feed
sitemap file
A-Z listing (archived)

Wikenigma - an Encyclopedia of Unknowns Wikenigma - an Encyclopedia of the Unknown

Reboxetine

Reboxetine, sold under the brand name Edronax, is a drug marketed as a treatment for Major Depressive Disorderplugin-autotooltip__plain plugin-autotooltip_bigMajor Depressive Disorder

Major depressive disorder (MDD), also known simply as depression, is a mental disorder characterized by at least two weeks of pervasive low mood.

Current estimates are that severe depression affects around 2% of the global population at any g…
,Attention-Deficit / Hyperactivity Disorder (ADHD)plugin-autotooltip__plain plugin-autotooltip_bigAttention-Deficit / Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental mental disorder. It's characterized by problems in paying attention, excessive activity, or difficulty in controlling behavior (typically not appro…
, and Panic Disorder - amongst others

It is said to work as a norepinephrine reuptake inhibitor (NRI) with special sensitivity for the norepinephrine transporter (NET).

Like Fluoxetineplugin-autotooltip__plain plugin-autotooltip_bigFluoxetine

Fluoxetine is a Selective Serotonin Reuptake Inhibitor (SSRI) used in the treatment of Major Depressive Disorderand Obsessive-Compulsive disorder etc.. It's marketed under the trade names Prozac™, Sarafem™, Fontex™ etc.

SSRIs are believed to act by inhibiti…
, an exact mechanism of action has not yet been found.

Despite widespread efforts to understand the mechanisms of action of antidepressant drugs, the requisite changes in neural function that underlie their therapeutic effects remain unclear. […] However, taken together with previous findings that chronic administration of fluoxetine also results in enhanced activation of LC neurons to a stressor (Page and Abercrombie 1997), our present findings suggest a possible shared mechanistic link between two distinct classes of antidepressant compounds. The exact nature of the mechanism remains unclear but it is likely to rely on the sensitivity of the noradrenergic system to stressors.

Source: Nature Neuropsychopharmacology Vol. 27, pp. 237–247(2002)

Note: A 2010 German study determined that Reboxetine works no better than a placeboplugin-autotooltip__plain plugin-autotooltip_bigPlacebo effect

Placebos are faux medications - typically lactose or microcrystalline cellulose - designed to act as inert, non-functional 'controls' in medical experiments. (There are also faux medical procedures, see section below)

From the beginnings of their use i…
.


    Share this page :

X

Dear reader : Do you have any suggestions for the site's content?

Ideas for new topics, and suggested additions / corrections for old ones, are always welcome.

If you have skills or interests in a particular field, and have suggestions for Wikenigma, get in touch !


Or, if you'd like to become a regular contributor . . . request a login password. Registered users can edit the entire content of the site, and also create new pages.

( The 'Notes for contributors' section in the main menu has further information and guidelines etc.)

Show another (random) page

DOKUWIKI IMPLEMENTATION DESIGN BY UNIV.ORG.UK AUGUST 2021